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Summary: Immunoreactive neurokinin A was measured in the cerebrospinal fluid of twelve patients with
Parkinson's disease and eleven normal subjects, using a sensitive and precise extraction/concentration radioim-
munoassay method. The mean value obtained in Parkinson's disease patients (13.2 ± 4.6 pmol/1) was lower
than that of the controls (17.4 ± 5.9). The tendency toward a significant decrease (p = 0.085) found in this
preliminary study could indicate that neurokinin Α-containing neurons are involved in the pathophysiology
of Parkinson's disease. In addition, the establishment of reference values for neurokinin A in cerebrospinal
fluid may provide a basis for further studies of this neuropeptide in neurological disorders.
Introduction
Neurokinin A and neurokinin B, two decapeptides
that belong to the kassinin-like tachykinin family,
have been identified as naturally ocurring peptides
from mammalian spinal cords (1, 2). Research in the
tachykinin field has focussed on clearing up the phys-
iological role of neurokinin A in central and periph-
eral neural transmission. As predicted from the ta-
chykinin structure of substance P and neurokinin A,
it has been reported that these two substances have
similar biological effects (3, 4). On the other hand,
certain differences in the pharmacological properties
of substance P and neurokinin A are basically ex-
plained by their interaction with different receptors;
the existence of three types of neurokinin receptor is
proposed, i. e. NK-1, NK-2 and NK-3, their respective
endogenous ligand being substance P, neurokinin A
and neurokinin B (5). Furthermore, two different
tachykinin mRNAs have been identified in mammals
and both of them also encode substance P (6), making
tissular coexistence of the two peptides highly prob-
able. In fact, the co-localization of substance P and
neurokinin A in several mammalian tissues has al-
ready been described (7, 8).
In rats, neurokinin A has been detected across brain
regions (9) and some effects on motor behaviour and
nociception have been demonstrated (3, 10). It has
been suggested that neurokinin A may have a neu-
rotransmitter/neuromodulator role in the substantia
nigra of rats (11). Since recent studies have revealed
interactions between the dopaminergic system and
neurokinin A in the striatonigral pathway (12, 13),
we have considered the possibility that neurokinin A
levels could be altered in those pathologies where the
dopaminergic system is affected.
The aim of this study was to establish reference values of
immunorective neurokinin A in human CSF using an
extraction/concentration/radioimmunoassay method,
and to compare the results with those obtained from
patients with Parkinson's disease.
Patients and Methods
Subjects
Lumbar CSF was collected from twelve patients (7 men, 5
women; aged 52 to 72 years) with Parkinson's disease, admitted
to the Neurology Department of the Valle Hebron Hospital for
a clinical investigation that included spinal puncture. Lumbar
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puncture was performed in the morning at bedrest after an
overnight fast. Patients had been moderately to severely affected
with symptoms for 1 to 11 years. Four were classified as stage
I or II, according to Hoen & Yahr (14), and eight were included
in stages III, IV, and V. Six patients received levodopa combined
with extracerebral inhibitor of dopa decarboxylase, five received
levodopa plus bromocriptine, and one was taking only brom-
ocriptine. Drug therapy was not stopped. The comparison
group included eleven patients from the Emergency Room (aged
50 to 73 years) who had symptoms requiring diagnostic lumbar
puncture, but in whom neurological or internal disorders were
excluded after careful investigation.
In both groups of patients the biochemical and cytologic CSF
analyses were normal and they gave informed consent before
participating.
Samples
The CSF samples for immunoreactive neurokinin A assays were
centrifuged. Aprotinin (Trasylol®, 1000 · 103 KIU/1) was added
to prevent enzymatic degradation, and samples were stored at
— 20 °C until assayed. Blood-tinged CSF was discarded.
Neurokinin A radioimmunoassay
Small columns packed with octadecasilyl silica (Ci8 Sep-pak,
Water Assoc., MA, USA) were used for sample extraction as
described previously (15). The extracted samples were taken to
dryness and resuspended in 500 μΐ of 0.05 mol/1 phosphate
buffer (pH = 7.4) containing 2 g/1 gelatin and 1 mmol/1 EDTA.
Immunoreactive neurokinin A concentrations were measured
using a commercially available 125I reagent pak RIA from
Amersham laboratories (Code IM 1681) and a neurokinin A
standard supplied by Sigma (St Louis, MO, USA). The anti-
serum provided in this reagent pack showed a 40% cross
reaction with neurokinin B and less than 0.1% for substance
R The duplicate RIA tubes containing either 200 μΐ of known
neurokinin A concentration (4.9 — 79.5 fmol/tube) or 200 μΐ of
dissolved extracted samples were incubated for 24 hours at 4 °C
with 100 μΐ of diluted antiserum (1/10) and 100 μΐ of labelled
neurokinin A (116 — 100 Bq). The separation of the free from
the antibody-bound peptide was performed by adding 100 μΐ
horse serum and 1 ml of polyethylene glycol (20% in distilled
water). After centrifugation (1500g, 20 min) the supernatant
was decanted and the radioactivity of the precipitate was meas-
ured in a gamma counter (LKB-Wallac, 1275 Minigamma with
a Databox 1222 calculation unit). Results were plotted as logit
versus log concentration of standards. Calculations to deter-
mine immunoreactive neurokinin A concentrations (pmol/1) in
the CSF samples corresponded to the volume extracted. Sen-
sitivity, defined as the amount of neurokinin A detectable at
the 95% confidence level, was 3.5 fmol/tube. Recovery values,
obtained by adding 40, 80, and 160 fmol of neurokinin A
standard to three different pools, were 95 ± 6%, 99 ± 6% and
97 ± 4% (n = 9). The intra-assay coefficient of variation was
studied at two concentrations, CV = 8.6% (x = 3.6 pmol/1;
n = 13) and CV = 5.7% (x = 5.8 pmol/1; n = 12). Specificity:
different aliquots of three extracted CSF pools, when analysed
by the described RIA, gave dose response curves parallel to
that of standard neurokinin A (fig. 1). A lineal relationship
between expected and found immunoreactive neurokinin A
values was observed: y = 0.90x + 0.054, r = 0.9765, P < 0.01
(n = 10).
Statistics
The Mann-Whitney U test was employed to determine signifi-
cant differences between groups. Correlation was established
by the Spearman correlation coefficient. Data are expressed as
mean ± standard deviation.
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Fig. 1. Effect of increasing aliquots of three extracted CSF
pools (ο, Δ, ·) on inhibition (B0) of maximum binding.
The curves obtained were parallel to that of the human
neurokinin A standard (·).
Results
The individual values of immunoreactive neurokinin
A in CSF of Parkinson's disease patients and controls
are shown in figure 2.
The mean value obtained in Parkinson's disease pa-
tients (13.2 ± 4.6 pmol/1) was lower than in the con-
trols (17.4 ± 5.9) (mean ± SD). The significance level
between the values obtained in the two groups studied
was ρ = 0.085.
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Fig. 2. Individual concentrations of neurokinin A in CSF of
control patients (n = 11) and patients with Parkinson's
disease (n = 12). Bars indicate mean value. Dashed lines
represent standard deviation.
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Discussion
To our knowledge, reference values for human CSF
immunoreactive neurokinin A have not hitherto been
determined. With the RIA method described we have
obtained good sensitivity, high recovery values and
satisfactory variation coefficients. Also, although our
antiserum recognizes neurokinin B, the parallelism of
the dilution curves proved that the immunoreactive
material determined behaved as the neurokinin A
standard. This was expected, since it has been dem-
onstrated, using highly specific antisera, that the con-
centrations of neurokinin A in several brain regions
in mammals are considerably higher than those of
neurokinin B (16). Therefore, the CSF tachykinin
immunoreactivity measured with our antiserum was
mostly due to neurokinin A activity. The establish-
ment of normal neurokinin A CSF values may pro-
vide a basis for further studies of this neuropeptide
in neurological disorders.
Studies on the regional distribution of tachykinins in
the rat central nervous system have shown that neu-
rokinin A is concentrated in areas known to be rich
in substance P, such as the midbrain, basal ganglia
and spinal cord, the brain region containing the high-
est concentration of both substance P and neurokinin
A being the substantia nigra (9). Also it has been
demonstrated that neurokinin A excites the nigral
dopaminergic neurons more effectively than substance
P, and exhibits a much greater action on locomotor
activity (11). The major biochemical characteristic of
Parkinson's disease is a degeneration of the dopami-
nergic neurons of the mesencephalon, although other
ascending systems are also affected (17). Significant
decreases in substance P have been found in the sub-
stantia nigra in Parkinson's disease (18,19) but similar
studies with neurokinin A have not been performed.
However, in this preliminary study we found a re-
duced CSF neurokinin A concentration in twelve Par-
kinson's disease patients (13.2 + 4.6 pmol/1), com-
pared with eleven controls (17.4 ± 5.9), with a distinct
tendency toward significance (p = 0.085). The meas-
urement of CSF neurokinin A concentration, in a
larger sample of patients, together with brain tissue
studies of this neuropeptide in Parkinson's disease,
may demonstrate a significant neurokinin A reduction
in Parkinsonian patients and indicate the involvement
of neurokinin Α-containing neurons in this disease.
Whether the loss of an excitatory neurokinin A input
to the substantia nigra contributes to the symptoms
of Parkinson's disease may be established in subse-
quent studies.
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